A STUDY ON CELLULAR IMMUNITY IN BLADDER CANCER, WITH SPECIAL REFERENCE TO LEUKOCYTE ADHERENCE INHIBITION TEST

Abstract

The capillary tube leukocyte adherence inhibition test (LAI test) was performed for determination of cellular immunity in the tumor bearing hosts with bladder cancer. The materials of this study were 43 cases, including 14 of either non-malignant disorders or malignant tumors other than bladder cancer in the urological field as the controls.
The antigen of 3M KCl extract was prepared from the tissues of transitional cell carcinoma of the bladder. The mean value of the percentages of non-adherence index (NAT) by LAI test from 28 cases of bladder cancer was 41.4±22.0. On the other hand, the percentage of 15 control subjects was only 14.7±11.0. It means that the 3M KCl extract from bladder cancer tissues is applicable to LAI test as common antigen. NAI in 5 malignant tumor bearing hosts with different histological types (2 prostatic adenocarcinomas, 2 renal cell carcinomas and 1 urethral squamous cell carcinoma) demonstrated a lower percentages of 17.6±8.9 in mean values as in benign control subjects. An additional experiment presented two exceptional cases of adenocarcinoma in the bladder which showed predominant activities on LAI test. Throughout the results described above, the necessary comments about the antigen specificities for LAI test were done.
Next attention was drawn to the LAI reactivities of bladder cancer patients with different advances of tumor growth. It was revealed that the LAI of the patients with initial growth of tumor (Stage A) were widely ranged, though the advances of tumor growth induced higher reactivities. It is of interest that the unresponsiveness of LAI was found in certain cases with metastasis, which were under critical conditions. The correlations between the delayed type hypersensitivity on skin and LAI test were not determined in this study. Further precise investigations should be undertaken.